VOCSARSCOVDep: Analysis of Volatile Organic Compounds in Exhaled Air and Sweat: Interest in Rapid Screening for COVID-19 Infection.

Sponsor
Hopital Foch (Other)
Overall Status
Recruiting
CT.gov ID
NCT04817371
Collaborator
(none)
192
1
4
18
10.6

Study Details

Study Description

Brief Summary

In the context of the actual pandemia of the Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which requires a better diagnostic strategy for the management of patients.

The study of volatile organic compounds (VOC) detected in exhaled air or in sweat, is an innovative research area for respiratory diseases. The analysis of VOC can be done either by the technique of the mass spectrometry which allows the identification of each VOC in the exhaled air or by the technique of electronic nose, simpler and faster, which provides an idea of the general profile of the VOC without identifying them. The VOC have shown their interest in some situations, such as diagnostic or prognostic tool in patients followed for thoracic tumorous pathology or bronchial or pulmonary vascular diseases.

Moreover, it has recently been shown that properly trained dogs would be able to detect an olfactory signature of SARS-CoV-2 infection with a specificity greater than 90%; this olfactory signature corresponds to VOCs detectable by the flair of dogs (Nosaïs-Covid19 study).

Validation of the diagnostic value of VOC analyzes by non-invasive and rapid methods (electronic nose analysis or mass spectrometry; detection by the scent of dogs) for the rapid detection and early diagnosis of a SARS-CoV-2 infection warrants the performance of this clinical study.

Condition or Disease Intervention/Treatment Phase
  • Device: Volatile Organic Compounds analysis (e-noses)
  • Other: Canine odor detection of Volatile Organic Compounds
  • Device: Volatile Organic Compounds analysis (mass spectrometry)
  • Device: Volatile Organic Compounds analysis in sweat (mass spectrometry)
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
192 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
Analysis of Volatile Organic Compounds in Exhaled Air and Sweat: Interest in Rapid Screening for SARS-CoV-2 Infection.
Actual Study Start Date :
Mar 1, 2021
Anticipated Primary Completion Date :
Sep 1, 2022
Anticipated Study Completion Date :
Sep 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Other: Symptomatic patients with positive PCR

Patients with symptoms of COVID-19 and whose PCR result is positive

Device: Volatile Organic Compounds analysis (e-noses)
VOC analysis in exhaled air with e-noses.

Other: Canine odor detection of Volatile Organic Compounds
VOC analysis in sweat by trained dogs.

Device: Volatile Organic Compounds analysis (mass spectrometry)
VOC analysis in exhaled air with mass spectrometry.

Device: Volatile Organic Compounds analysis in sweat (mass spectrometry)
VOC analysis in sweat with mass spectrometry.

Other: Symptomatic patients with positive PCR for other respiratory virus

Patients with symptomatic respiratory disease of infectious origin with negative RT-PCR for SARS-CoV-2 and positive RT-PCR for other respiratory viruses

Device: Volatile Organic Compounds analysis (e-noses)
VOC analysis in exhaled air with e-noses.

Other: Canine odor detection of Volatile Organic Compounds
VOC analysis in sweat by trained dogs.

Device: Volatile Organic Compounds analysis (mass spectrometry)
VOC analysis in exhaled air with mass spectrometry.

Device: Volatile Organic Compounds analysis in sweat (mass spectrometry)
VOC analysis in sweat with mass spectrometry.

Other: Asymptomatic patients or healthy volunteers

Patients or healthy volunteers with negative RT-PCR and negative serology

Device: Volatile Organic Compounds analysis (e-noses)
VOC analysis in exhaled air with e-noses.

Other: Canine odor detection of Volatile Organic Compounds
VOC analysis in sweat by trained dogs.

Device: Volatile Organic Compounds analysis (mass spectrometry)
VOC analysis in exhaled air with mass spectrometry.

Device: Volatile Organic Compounds analysis in sweat (mass spectrometry)
VOC analysis in sweat with mass spectrometry.

Other: Volunteers or patients vaccinated against COVID-19

Volunteers or patients vaccinated against COVID-19 (complete vaccination scheme)

Device: Volatile Organic Compounds analysis (e-noses)
VOC analysis in exhaled air with e-noses.

Other: Canine odor detection of Volatile Organic Compounds
VOC analysis in sweat by trained dogs.

Device: Volatile Organic Compounds analysis (mass spectrometry)
VOC analysis in exhaled air with mass spectrometry.

Device: Volatile Organic Compounds analysis in sweat (mass spectrometry)
VOC analysis in sweat with mass spectrometry.

Outcome Measures

Primary Outcome Measures

  1. The first co-objective of this experimental study is to determine if VOCs analyzed by electronic noses are of interest for the diagnosis of an infection by SARS-CoV-2 (COVID-19) infection. [1 day]

    Identification of VOC profiles specific to the SARS-CoV-2 (VOC analysis by electronic noses) on exhalates collected under resting breathing conditions between patients with symptoms suggestive of COVID-19 and SARS-CoV-2 infection confirmed by RT-PCR, those whose infection is ruled out on the basis of the negativity RT-PCR and clinical/radiological data (non-COVID control patients), and those with another symptomatic respiratory viral infection confirmed by positive PCR for viruses other than SARS-CoV-2 other than SARS-CoV-2.

  2. The second co-objective of this experimental study is to determine if VOCs analyzed by mass spectrometry is of interest for the diagnosis of an infection by SARS-CoV-2 (COVID-19) infection. [1 day]

    Identification of VOC profiles specific to the SARS-CoV-2 (VOC analysis by mass spectrometry) on exhalates collected under resting breathing conditions between patients with symptoms suggestive of COVID and SARS-CoV-2 infection confirmed by RT-PCR, those whose infection is ruled out on the basis of the negativity RT-PCR and clinical/radiological data (non-COVID control patients), and those with another symptomatic respiratory viral infection confirmed by positive PCR for viruses other than SARS-CoV-2 other than SARS-CoV-2.

Secondary Outcome Measures

  1. Identify the nature of VOCs associated with infection by SARS-CoV-2 by mass spectrometry in exhaled air and in sweat [1 day]

    The equivalences and differences in nature of VOCs associated with infection with SARS-CoV-2 between exhaled air and sweat identified by mass spectrometry.

  2. Assessment of the specificity and sensitivity of canine olfactory detection of COVs associated with infection by SARS-CoV-2 (COVID-19) [1 day]

    Success rate of dogs trained in detecting COVID-19 from sweat samples taken from participating patients. The status of patients (infected and uninfected with COVID-19 from the result of the PCR) will be compared to the result of the canine olfactory detection of COVID-19 in sweat samples.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Subject included in the Foch Hospital :

  • Patients managed at the Foch Hospital with RT-PCR screening for SARS-CoV-2 infection

  • Healthy volunteers among the hospital staff, asymptomatic, for whom an RT-PCR SARS-CoV-2 is indicated or recommended.

  • Healthy hospital volunteers vaccinated against COVID (full vaccination schedule completed)

  • At least 18 years of age;

  • Fluency in the French language;

  • Have signed a consent form;

  • Be affiliated with a health insurance plan.

Exclusion Criteria:
  • Pregnant woman

  • Patient deprived of liberty by judicial or administrative decision

Contacts and Locations

Locations

Site City State Country Postal Code
1 Foch hospital Suresnes France 92151

Sponsors and Collaborators

  • Hopital Foch

Investigators

  • Principal Investigator: Philippe Devillier, PhD, Hopital Foch

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Hopital Foch
ClinicalTrials.gov Identifier:
NCT04817371
Other Study ID Numbers:
  • 2021_0013
First Posted:
Mar 26, 2021
Last Update Posted:
Aug 3, 2022
Last Verified:
Aug 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 3, 2022